Correlation Between Genetic Variations and Serum Level of Interleukin 28B with Virus Genotypes and Disease Progression in Chronic Hepatitis C Virus Infection

Overview

Journal J Immunol Res

Publisher Wiley

Specialty Allergy & Immunology

Date 2015 Mar 27

PMID 25811035

Citations 16

Authors

Ahmed Al-Qahtani

Mashael Al-Anazi

Ayman A Abdo

Faisal M Sanai

Waleed Al-Hamoudi

Khalid A Alswat

Hamad I Al-Ashgar

Mohammed Q Khan

Ali Albenmousa

Nisreen Khalaf

Nisha Viswan

Mohammed N Al-Ahdal

Affiliations

Soon will be listed here.

Abstract

Recent studies have demonstrated that polymorphisms near the interleukin-28B (IL-28B) gene could predict the response to Peg-IFN-a/RBV combination therapy in HCV-infected patients. The aim of the study was to correlate the serum level of IL28B in HCV-infected patients with virus genotype/subgenotype and disease progression. IL28B serum level was detected and variations at five single nucleotide polymorphisms (SNPs) in IL28B gene region were genotyped and analyzed. The variation of IL28B genetic polymorphisms was found to be strongly associated with HCV infection when healthy control group was compared to HCV-infected patients with all P values <0.0001. Functional analysis revealed that subjects carrying rs8099917-GG genotype had higher serum level of IL28B than those with GT or TT genotypes (P = 0.04). Also, patients who were presented with cirrhosis (Cirr) only or with cirrhosis plus hepatocellular carcinoma (Cirr+HCC) had higher levels of serum IL28B when compared to chronic HCV-infected patients (P = 0.005 and 0.003, resp.). No significant association was found when serum levels of IL28B were compared to virus genotypes/subgenotypes. This study indicates that variation at SNP rs8099917 could predict the serum levels of IL28B in HCV-infected patients. Furthermore, IL28B serum level may serve as a useful marker for the development of HCV-associated sequelae.

Citing Articles

Effect of immunogenetics polymorphism and expression on direct-acting antiviral drug response in chronic hepatitis C.

Abdelaziz A, Abdelsameea E, Abdel-Samiee M, Ghanem S, Wahdan S, Elsherbiny D Clin Exp Med. 2024; 24(1):184.

PMID: 39117877 PMC: 11310263. DOI: 10.1007/s10238-024-01432-x.

Understanding torquetenovirus (TTV) as an immune marker.

Gore E, Gard L, Niesters H, Van Leer Buter C Front Med (Lausanne). 2023; 10:1168400.

PMID: 37384041 PMC: 10296770. DOI: 10.3389/fmed.2023.1168400.

Association of Interleukin-28B Polymorphisms (rs12979860 C/T, rs12980275 A/G, rs8099917 T/G) and Risk of Hepatocellular Carcinoma in an Iranian Population.

Hajizadeh L, Mansour Samaei N, Bazgir A, Agha Gholizadeh M, Khosravi A Middle East J Dig Dis. 2023; 14(1):118-123.

PMID: 36619736 PMC: 9489329. DOI: 10.34172/mejdd.2022.264.

Prevalence of exposure to pharmacogenetic drugs by the Saudis treated at the health care centers of the Ministry of National Guard.

Alshabeeb M, Alyabsi M, Paras B Saudi Pharm J. 2022; 30(8):1181-1192.

PMID: 36164570 PMC: 9508627. DOI: 10.1016/j.jsps.2022.06.013.

Association of IL28B (IFNL3) rs12979860 mRNA levels, viral load, and liver function among HCV genotype 1a patients.

Mousavi Nasab S, Vasmehjani A, Kaghazian H, Mardani R, Zali F, Ahmadi N Gastroenterol Hepatol Bed Bench. 2020; 12(Suppl1):S156-S162.

PMID: 32099617 PMC: 7011071.

References

Murphy D, Willems B, Deschenes M, Hilzenrat N, Mousseau R, Sabbah S . Use of sequence analysis of the NS5B region for routine genotyping of hepatitis C virus with reference to C/E1 and 5' untranslated region sequences. J Clin Microbiol. 2007; 45(4):1102-12. PMC: 1865836. DOI: 10.1128/JCM.02366-06. View

Lavanchy D . The global burden of hepatitis C. Liver Int. 2009; 29 Suppl 1:74-81. DOI: 10.1111/j.1478-3231.2008.01934.x. View

Marcello T, Grakoui A, Barba-Spaeth G, Machlin E, Kotenko S, MacDonald M . Interferons alpha and lambda inhibit hepatitis C virus replication with distinct signal transduction and gene regulation kinetics. Gastroenterology. 2006; 131(6):1887-98. DOI: 10.1053/j.gastro.2006.09.052. View

Ank N, West H, Bartholdy C, Eriksson K, Thomsen A, Paludan S . Lambda interferon (IFN-lambda), a type III IFN, is induced by viruses and IFNs and displays potent antiviral activity against select virus infections in vivo. J Virol. 2006; 80(9):4501-9. PMC: 1472004. DOI: 10.1128/JVI.80.9.4501-4509.2006. View

Robek M, Boyd B, Chisari F . Lambda interferon inhibits hepatitis B and C virus replication. J Virol. 2005; 79(6):3851-4. PMC: 1075734. DOI: 10.1128/JVI.79.6.3851-3854.2005. View

Siren J, Pirhonen J, Julkunen I, Matikainen S . IFN-alpha regulates TLR-dependent gene expression of IFN-alpha, IFN-beta, IL-28, and IL-29. J Immunol. 2005; 174(4):1932-7. DOI: 10.4049/jimmunol.174.4.1932. View

Barrera J, Bruguera M, Ercilla M, Gil C, Celis R, Gil M . Persistent hepatitis C viremia after acute self-limiting posttransfusion hepatitis C. Hepatology. 1995; 21(3):639-44. View

Hadziyannis S, Sette Jr H, Morgan T, Balan V, Diago M, Marcellin P . Peginterferon-alpha2a and ribavirin combination therapy in chronic hepatitis C: a randomized study of treatment duration and ribavirin dose. Ann Intern Med. 2004; 140(5):346-55. DOI: 10.7326/0003-4819-140-5-200403020-00010. View

Kotenko S, Gallagher G, Baurin V, Lewis-Antes A, Shen M, Shah N . IFN-lambdas mediate antiviral protection through a distinct class II cytokine receptor complex. Nat Immunol. 2002; 4(1):69-77. DOI: 10.1038/ni875. View

10.

Sheppard P, Kindsvogel W, Xu W, Henderson K, Schlutsmeyer S, Whitmore T . IL-28, IL-29 and their class II cytokine receptor IL-28R. Nat Immunol. 2002; 4(1):63-8. DOI: 10.1038/ni873. View

11.

Seeff L . Natural history of chronic hepatitis C. Hepatology. 2002; 36(5 Suppl 1):S35-46. DOI: 10.1053/jhep.2002.36806. View

12.

Bruix J, Sherman M, Llovet J, Beaugrand M, Lencioni R, Burroughs A . Clinical management of hepatocellular carcinoma. Conclusions of the Barcelona-2000 EASL conference. European Association for the Study of the Liver. J Hepatol. 2001; 35(3):421-30. DOI: 10.1016/s0168-8278(01)00130-1. View

13.

McHutchison J, Lawitz E, Shiffman M, Muir A, Galler G, McCone J . Peginterferon alfa-2b or alfa-2a with ribavirin for treatment of hepatitis C infection. N Engl J Med. 2009; 361(6):580-93. DOI: 10.1056/NEJMoa0808010. View

14.

Ge D, Fellay J, Thompson A, Simon J, Shianna K, Urban T . Genetic variation in IL28B predicts hepatitis C treatment-induced viral clearance. Nature. 2009; 461(7262):399-401. DOI: 10.1038/nature08309. View

15.

Tanaka Y, Nishida N, Sugiyama M, Kurosaki M, Matsuura K, Sakamoto N . Genome-wide association of IL28B with response to pegylated interferon-alpha and ribavirin therapy for chronic hepatitis C. Nat Genet. 2009; 41(10):1105-9. DOI: 10.1038/ng.449. View

16.

Suppiah V, Moldovan M, Ahlenstiel G, Berg T, Weltman M, Abate M . IL28B is associated with response to chronic hepatitis C interferon-alpha and ribavirin therapy. Nat Genet. 2009; 41(10):1100-4. DOI: 10.1038/ng.447. View

17.

Thomas D, Thio C, Martin M, Qi Y, Ge D, OhUigin C . Genetic variation in IL28B and spontaneous clearance of hepatitis C virus. Nature. 2009; 461(7265):798-801. PMC: 3172006. DOI: 10.1038/nature08463. View

18.

Abe H, Ochi H, Maekawa T, Hayes C, Tsuge M, Miki D . Common variation of IL28 affects gamma-GTP levels and inflammation of the liver in chronically infected hepatitis C virus patients. J Hepatol. 2010; 53(3):439-43. DOI: 10.1016/j.jhep.2010.03.022. View

19.

Fabris C, Falleti E, Cussigh A, Bitetto D, Fontanini E, Bignulin S . IL-28B rs12979860 C/T allele distribution in patients with liver cirrhosis: role in the course of chronic viral hepatitis and the development of HCC. J Hepatol. 2010; 54(4):716-22. DOI: 10.1016/j.jhep.2010.07.019. View

20.

Zhang L, Miao L, Han F, Dou X . [Cytokine levels in serum of patients with chronic hepatitis C and its significance]. Xi Bao Yu Fen Zi Mian Yi Xue Za Zhi. 2011; 27(3):301-3. View